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Abstract
Purpose: To investigate the usefulness of contrast-
enhanced three-dimensional ultrasonography (CE 3D
US) for differential diagnosis of solid pancreatic lesions.
Methods: Eighty-five patients with solid pancreatic
lesions who underwent CE 3D US were retrospectively
analyzed. Sixty-four patients had pancreatic ductal
adenocarcinoma (PDAC), 10 had mass-forming pancre-
atitis (MFP), and 11 had neuroendocrine tumor (NET).
Two blinded readers evaluated the enhancement patterns
using four features: vascularity in the arterial phase,
vascularity in the venous phase, vessel location, and
vessel form. Vascularity in both phases was classified as
hypervascular, isovascular, or hypovascular. Vessel loca-
tion was classified into peritumoral or intratumoral.
Vessel form was classified into fine or irregular. Kappa
values were used to assess inter-reader agreement. The
institutional review board approved this study, and
informed consent was obtained.
Results: Kappa values of the four features were 0.75,
0.72, 0.85, and 0.65, which were graded as good or
excellent. The most typical combined enhancement
pattern in PDAC was hypovascularity in both phases
with peritumoral and irregular vessels; MFP was isovas-
cular in both phases with intratumoral and fine vessels;
and NETs were hypervascular in both phases with
intratumoral and irregular vessels. The sensitivity and
positive predictive value of the three patterns were 93.8%
and 96.7% for the PDAC pattern, 80.0% and 100% for
the MFP pattern, and 81.8%, and 69.2% for the NET
pattern, respectively. The accuracy of these diagnostic
criteria was 90.5%.
Conclusion: CE 3D US allows detailed visualization of
the enhancement patterns of various pancreatic lesions





A conventional ultrasonography (US) is ﬁrst performed
for the evaluation of solid pancreatic lesions [1–3].
However, this method alone cannot be used for the dif-
ferential diagnosis of solid pancreatic lesions because
most of these lesions are similarly hypoechoic on B-mode
US [4, 5]. Doppler US is widely used to evaluate the
relatively large vessels around the pancreas [6–8]; how-
ever, it cannot clearly reveal the vessels in solid pancre-
atic lesions.
Recently, contrast-enhanced US (CE US) has become
increasingly important for the characterization of solid
pancreatic lesions because it provides real-time scanning
compared with contrast-enhanced computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) [9, 10].
Sonazoid (Daiichi Sankyo, Tokyo, Japan) is a second-
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stabilized by a phospholipid monolayer shell [11, 12].
Sonazoid permits repetitive scanning and provides pre-
cise enhanced images. Although several studies have
indicated the importance of transabdominal CE US
using Levovist (a first-generation contrast agent com-
prising galactose–palmitic acid; Shering AG, Berlin,
Germany) or SonoVue (a second-generation contrast
agent comprising sulfur hexafluoride-filled microbubbles
with a phospholipid shell; Bracco Inc, Milan, Italy) for
the characterization of pancreatic diseases, no study has
reported the use of Sonazoid [13–21].
Sonazoid-enhanced US usually use a low mechanical
index (MI) contrast mode [11]. In the case of solid pan-
creatic lesions, a low MI contrast mode setting does not
destroy the microbubbles and enables the continuous
observation of tumor enhancement. However, this mode
cannot eliminate the background B-mode sufficiently,
which makes it difficult to clearly evaluate minute ves-
sels. In contrast, a high MI contrast mode setting can
eliminate the background B-mode and provide sensitive
visualization of tumor vessels [22–24].
Three-dimensional US (3D US) images provide more
spatial information compared with two-dimensional
(2D) US images [22, 25, 27]. With advances in 3D US
technology, volume data can be acquired simply and
rapidly with the automatic scan function using a
mechanically swept curved array. Tomographic ultra-
sound images (TUIs) are reconstructed by dividing the
images obtained from the volume data into multiple
parallel slices in three orthogonal planes, which is similar
to that in CT and MRI. In addition, sonographic angi-
ograms similar to radiographic angiographic images are
reconstructed for visualizing tumor vessels in three
dimensions [24]. A combination of TUIs and sono-
graphic angiograms can be used to simultaneously eval-
uate the vascularity in solid pancreatic lesions and the
pancreatic parenchyma, providing a clear 3D view of the
tumor vessels.
The aim of the present study was to investigate the




Between February 2007 and March 2012, 85 consecutive
patients with solid pancreatic lesions were retrospectively
analyzed, including 64 patients with pancreatic ductal
adenocarcinoma (PDAC), 10 with mass-forming pan-
creatitis (MFP), and 11 with neuroendocrine tumor
(NET). All lesions could be detected by conventional US,
and all patients underwent CE 3D US at the Yokohama
City University Medical Center. After the CE 3D US
examinations, pathological analyses were performed to
achieve deﬁnitive diagnoses. Twenty-two patients were
treated surgically, and in the remaining 63 patients,
diagnosis was performed by analysis of the biopsy
specimen obtained by endosonographic ﬁne-needle
aspiration biopsy (n = 45), endoscopic biopsy (n = 11),
or percutaneous biopsy (n = 7). MFP was also con-
firmed by its typical appearance on multi-detector CT for
at least 1 year during the follow-up period. The institu-
tional review board approved this study, and informed
that consent was obtained from all patients before the
CE 3D US examinations were conducted.
Equipment and contrast agent
The examinations were performed using a LOGIQ 7
ultrasound imaging system and a mechanically swept
curved array (GE Healthcare, Milwaukee, WI) with a
frequency of 2.0–5.5 MHz. Two sonographers (K.N. and
H.M.) with 10 and 3 years of experience in abdominal
CE US, respectively, performed these examinations. The
coded harmonic angio mode, a high MI contrast mode
(MI = 0.6–0.9) at 8–13 frames/s, was used, and the focal
zone was set beneath the solid pancreatic lesions. All
patients received an intravenous bolus injection of
0.2 mL of Sonazoid via the antecubital vein, followed by
infusion of a 5 mL 5% glucose solution prior to the
automatic sweeping of the transducer.
The autosweep 3D function was used for image
acquisition in two phases: 3–4 times in the arterial phase
(10–60 s after injection), and 2 times in the venous phase
(90–180 s after injection). A volume angle of between 40
and 80 (mean, 57) was selected to simultaneously ac-
quire images of focal pancreatic lesions and pancreatic
parenchyma. The acquisition time was 1.3 s for a volume
angle of 40 and 3.2 s for a volume angle of 80.
Acquisition was performed in various directions to avoid
artifacts such as gastrointestinal gas, major vessels, and
calciﬁcation around the pancreas.
Image reconstruction
After volume data acquisition, we could check the CE
3D US images frame by frame, similar to the 2D image.
Then, the best images were selected for 3D image
reconstruction, which was performed using an in-built
function of the LOGIQ 7 ultrasound system. The volume
of interest was depicted as a cuboid region in which the
three orthogonal imaging planes were reconstructed:
from the front to the back through the cuboid region,
deﬁned as plane A; from the left to the right, deﬁned as
plane B; and from the top to the bottom, deﬁned as plane
C [24]. The time required to perform this procedure was
approximately 1 min. TUIs in each plane were recon-
structed by dividing the images obtained from the vol-
ume data into four or six parallel slices, so that the solid
pancreatic lesions and pancreatic parenchyma could be
observed simultaneously. The distance between any two
slices was approximately 2–10 mm. The time required to
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perform this procedure was approximately 20 s for plane
A and 30 s for plane B or C. Sonographic angiograms
were reconstructed by two kinds of rendering modes that
allowed 3D visualization of the vessels and enhancement
of solid pancreatic lesions. The maximum intensity mode
to display maximal gray values in the volume of interest
was used to visualize vessels in solid pancreatic lesions
(Fig. 1B). The average intensity mode to display average
gray values in the volume of interest was used to com-
pare vascularity of a solid pancreatic lesion and pan-
creatic parenchyma (Figs. 2F, 3C). The mean time
required for this procedure was approximately 1 min.
Fig. 1. CE 3D US images acquired in the transverse plane of a
71-year-old woman with NET (maximum diameter, 38 mm) in
the pancreatic head. A TUIs of CE 3D US (plane A) in the arterial
phase show a hypervascular lesion (arrowheads) compared with
the parenchyma in the pancreatic body (asterisk). B Sono-
graphic angiogram in the arterial phase, rendered in the maxi-
mum intensity mode, shows a markedly dilated tortuous vessel,
classified as an intratumoral and irregular vessel (arrow).
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Total time for 3D image reconstruction was no more
than 5 min for each lesion. The volume data, TUIs, and
sonographic angiograms were stored electronically.
Image evaluation
After all the examinations were completed, the two
above-mentioned sonographers deﬁned the evaluation
criteria (Fig. 4). Vascularity in the arterial and venous
phases was classified as follows: hypervascular, higher
echogenicity than that of the pancreatic parenchyma;
isovascular, equal echogenicity to that of the pancreatic
parenchyma; and hypovascular, lower echogenicity than
that of the pancreatic parenchyma. Vessel patterns were
characterized by vessel location and form. Vessels
located only at the peripheral area of the focal lesions
were termed ‘‘peritumoral vessels’’ and those located at
both the peripheral and central areas were termed ‘‘in-
tratumoral vessels.’’ With regard to the vessel form, ‘‘fine
vessels’’ were thin, minute, and orderly branched, while
‘‘irregular vessels’’ were winding, tortuous, and variably
shaped. Two readers (K.S. and H.F.) with 5 and 3 years
of experience in CE 3D US imaging of the pancreas,
blinded to the final diagnosis and other radiological
information, independently interpreted all the images
according to the evaluation criteria, respectively. If the
readers obtained discordant results, then they arrived at
the final classification after a consensus meeting. After
pattern classification, the combination of enhancement
patterns was summarized.
Fig. 2. CE 3D US images acquired in the transverse plane of
a 43-year-old man with PDAC (maximum diameter, 38 mm) in
the pancreatic body. A–D Hypovascular lesions (arrowheads)
are clearly seen in three orthogonal planes in the arterial phase.
Small green squares show the center of a lesion. (A An image
for navigation of the following planes; B plane A, from the front
to the back; C plane B, from the left to the right; and D plane C,
from the top to the bottom). E TUIs of CE 3D US (plane A) in the
arterial phase show a hypovascular lesion (arrowheads) com-
pared with the parenchyma in the pancreatic head (asterisks)
with peritumoral and fine vessels. The dilated main pancreatic
duct appears as a non-enhanced area in the caudal part of the
lesion (arrow). F Sonographic angiogram in the arterial phase,
rendered in the average intensity mode, shows the hypovas-
cular lesion in the pancreatic body (arrowheads) compared with
the parenchyma (asterisk). The splenic artery with encasement
by tumor invasion (arrow) and common hepatic artery (curved
arrow) is clearly seen posterior to the pancreas.
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Statistical analysis
Kappa values were used to assess inter-reader agreement
regarding the characteristic enhancement patterns of solid
pancreatic lesions in each classiﬁcation before consensus
meeting. Inter-reader agreement was graded as poor
(<0.20), moderate (0.20–0.40), fair (0.40–0.60), good
(0.60–0.80), or excellent (0.80–1.00). The enhancement
patterns, vascularity in the arterial and venous phases,
vessel location, and vessel form were used to establish the
diagnostic criteria for solid pancreatic lesions. We calcu-
lated the positive predictive value (PPV) of PDAC, MFP,
and NET for each of the nine combination patterns and
deﬁned them as the PDAC, MFP, and NET patterns,
according to the largest PPV.Next, the sensitivity andPPV
Fig. 2. continued
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for differential diagnosis of each pattern-based classiﬁca-
tion were calculated. Accuracy was deﬁned by the per-
centage of patients who were diagnosed correctly. All
statistical analyses were performed using SPSS software
(version 19; SPSS, Tokyo, Japan).
Results
Patient characteristics
Characteristics of the patients included in this study are
summarized in Table 1. The patients consisted of 47 men
and 38 women. The mean age of the patients was 68 years
(range, 41–83 years). In total, 57 of the lesions in these pa-
tients were located in the pancreatic head and 28 were lo-
cated in thebodyand tail.The sizeof the lesions ranged from
10 to 62 mm (average, 28 mm) in diameter on B-mode US.
Enhancement patterns according to
each reader
The enhancement patterns observed on CE 3D US by
each of the two readers and the kappa values are sum-
marized in Table 2. In 60 (71%) of the 85 cases, the
readers obtained completely concordant results in each
classification. In the remaining 25 (29%) cases, discor-
dant results were obtained; more specifically, results re-
lated to the vascularity in the arterial phase and the
venous phase, vessel location, and vessel form were dis-
cordant in 8 (9%), 9 (11%), 5 (6%), and 10 (12%) of the
85 cases, respectively. The kappa values of vascularity in
the arterial and venous phases, vessel location, and vessel
form were 0.75, 0.72, 0.85, and 0.65, respectively. They
were graded as good or excellent.
Fig. 3. Conventional 3D US and CE 3D US images acquired
in the transverse plane of a 78-year-old woman with MFP
(maximum diameter, 33 mm) in the pancreatic head. A TUI of
3D US (plane A) in the B-mode shows a hypoechoic lesion in
the pancreatic head (arrowheads). The image on the lower
right shows the pancreatic parenchyma in the pancreatic body
(asterisk). B TUIs of CE 3D US (plane A) in the arterial phase
show an isovascular lesion (arrowheads) compared with the
pancreatic parenchyma (asterisk). Dense fine vessels are
seen in a whole lesion, hypoechoic on B-mode US, similar to
the pancreatic parenchyma. C Sonographic angiogram in the
arterial phase, rendered in the average intensity mode, shows
homogeneous enhancement (arrowheads) of both the pan-
creatic head and body. Superior mesenteric artery (arrow)
and abdominal aorta (curved arrow) appear around pancreas.
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Final enhancement patterns
In the 25 cases where the readers obtained discordant
results, they arrived at the ﬁnal classiﬁcation after a
consensus meeting. The enhancement patterns agreed
upon after the consensus meeting are shown in Table 3.
Vascularity
In the arterial phase, 54 (84%) of the 64 PDACs were
hypovascular; 9 (90%) of the 10 MFP were isovascular;
and 7 (64%) of the 11 NETs were hypervascular. In the
venous phase, 60 (94%) of the 64 PDACs were hypo-
vascular; 9 (90%) of the 10 MFP were isovascular; and 6
(55%) and 4 (36%) of the 11 NETs were hypervascular
and isovascular, respectively. One (50%) of the 2 PDACs
that were hypervascular in the arterial phase changed to
isovascular in the venous phase. Six (75%) of the 8
PDACs that were isovascular in the arterial phase
changed to hypovascular in the venous phase. These
‘‘washout changes’’ were a characteristic ﬁnding for
PDACs; in contrast, these changes were not found in
MFP and in 9 (82%) of the 11 NETs.
Vessel patterns
Regarding the vessel location, 31 (48%) and 33 (52%) of
the 64 PDACs were located in the peritumoral and
Fig. 3. continued
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intratumoral vessels, respectively. In contrast, all MFP
and NET lesions were located in the intratumoral ves-
sels. Regarding the vessel form, of the 64 PDAC pa-
tients, 25 (39%) had ﬁne vessels and 39 (61%) had
irregular vessels. Nine (90%) of the 10 MFP patients
had ﬁne vessels. In contrast, all NET patients had
irregular vessels.
Combinations of enhancement patterns
Combinations of enhancement patterns are summarized in
Table 4. These patterns were characterized by four fea-
tures: vascularity in the arterial phase, vascularity in the
venous phase, vessel location, and vessel form. A total of
36 combinations are possible. However, all the lesions
were classified into nine patterns in the present study. PPV
was calculated from the results, and each combinationwas
defined as a PDAC, MFP, or NET pattern, according to
the largest PPV. Sixty-two lesions showing patterns 5, 6, 7,
8, and 9 were defined as the PDAC pattern. The most
typical pattern was hypovascular in both the phases with
peritumoral irregular vessels. One case of MFP and one
case of NET demonstrated the PDAC pattern. Eight le-
sions showing pattern 3 were defined as the MFP pattern.
This pattern was isovascular in both the phases with in-
tratumoral fine vessels. Neither PDAC nor NET lesion
demonstrated the MFP pattern. Thirteen lesions showing
patterns 1 and 4 were defined as the NET pattern. The
most typical pattern was hypervascular in both the phases
with intratumoral irregular vessels. Three PDAC lesions
and oneMFP lesion demonstrated theNETpatterns. Two
lesions showing pattern 2 could not be defined because
PPVs for NETs and PDACs were equal.
For the ﬁnal pathological diagnosis, the sensitivity
and PPV for each of the three patterns, on the basis of
the combined enhancement patterns, were 93.8% [95%
conﬁdence interval (CI) 89.1–98.7%] and 96.7% (95% CI
95.2–100%) for the PDAC pattern; 80.0% (95% CI 70.0–
100%) and 100% (95% CI 100–100%) for the MFP pat-
tern; and 81.8% (95% CI 72.7–100%) and 69.2% (95% CI
53.8–97.6%) for the NET pattern, respectively. In total,
77 of the 85 cases, which included 60 of the 64 PDACs, 8
of the 10 MFP, and 9 of the 11 NETs, were correctly
diagnosed using the combination-based approach.
Accordingly, the accuracy of this diagnostic method was
90.5% (95% CI 90.4–90.8%).
Fig. 4. CE 3D US images showing the typical enhancement
patterns of solid pancreatic lesions. A A hypervascular lesion
(arrowheads) compared with the pancreatic parenchyma
(asterisk) with intratumoral and irregular vessels (arrows). B
An isovascular lesion (arrowheads) compared with the pan-
creatic parenchyma (asterisk) with intratumoral and fine
vessels (arrows). C A hypovascular lesion (arrowheads)
compared with the pancreatic parenchyma (asterisk) with
peritumoral and fine vessels (arrows). D A hypovascular le-
sion (arrowheads) compared with the pancreatic parenchyma
(asterisk) with peritumoral and irregular vessels (arrows). E
Hypovascular lesions (arrowheads) compared with the pan-
creatic parenchyma (asterisk) with intratumoral and irregular
vessels (arrows).
b
Table 1. Clinical characteristics of the subjects with solid pancreatic





Age (mean, range, years) 68, 41–83
Sex (male/female) 47/38
Location of lesions (pancreatic head/
pancreatic body and tail)
57/28
Diameter of lesions (mean, range, mm) 28, 10–62
Diagnosis confirmed by surgery/biopsy 19/65
PDAC pancreatic ductal adenocarcinoma, MFP mass-forming pan-
creatitis, NET neuroendocrine tumor
Table 2. Enhancement patterns
Reader 1 Reader 2 Kappa value
PDAC MFP NET PDAC MFP NET
Arterial phase 0.75
Hypervascular 3(2/64) 0(0/10) 73(8/11) 3(2/64) 0(0/10) 64(7/11)
Isovascular 10(7/64) 100(10/10) 27(3/11) 14(9/64) 90(9/10) 36(4/11)
Hypovascular 86(55/64) 0(0/10) 0(0/11) 83(53/64) 10(1/10) 0(0/11)
Venous phase 0.72
Hypervascular 2(1/64) 0(0/10) 64(7/11) 2(1/64) 0(0/10) 64(7/11)
Isovascular 2(1/64) 90(9/10) 36(4/11) 6(4/64) 80(8/10) 27(3/11)
Hypovascular 97(62/64) 10(1/10) 0(0/11) 83(53/64) 20(2/10) 9(1/11)
Vessel location 0.85
Peritumoral 52(33/64) 0(0/10) 0(0/11) 52(33/64) 0(0/10) 0(0/11)
Intratumoral 48(31/64) 100(10/10) 100(11/11) 48(31/64) 100(10/10) 100(11/11)
Vessel form 0.65
Fine 16(10/64) 70(7/10) 0(0/11) 16(10/64) 90(9/10) 0(0/11)
Irregular 84(54/64) 30(3/10) 100(11/11) 84(54/64) 10(1/10) 100(11/11)
Data are percentages; data in parentheses are numbers of the solid pancreatic lesions
PDAC pancreatic ductal adenocarcinoma, MFP mass-forming pancreatitis, NET neuroendocrine tumor
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Discussion
There are no published reports regarding the diagnosis of
pancreatic disease using CE 3D US with Sonazoid.
According to our experience, the vessels in the pancreas
are detectable from approximately 10 s after infusion,
and the pancreatic parenchyma is rapidly enhanced until
approximately 30 s. Subsequently, the enhancement of
the pancreatic parenchyma persists until approximately
60 s and then gradually reduces from 90 to 180 s. Based
on these features, we have deﬁned two phases, i.e., the
arterial phase of 10–60 s and the venous phase of 90–
180 s. With respect to differences from other contrast
agents, Sonazoid is longer acting than Levovist [15, 16,
22–24]. This feature enables repetitive autosweep acqui-
sitions in the arterial phase, which is essential for CE 3D
US. Moreover, with Sonazoid, we can use high MI
contrast mode settings that provide precise CE 3D US
images. In contrast, this mode is not available for So-
noVue [17–20].
In this study, CE 3D US was used to simultaneously
evaluate solid pancreatic lesions and pancreatic paren-
chyma. Moreover, the combinations of enhancement
patterns obtained using CE 3D US revealed the charac-
teristic features of speciﬁc solid pancreatic lesions such as
PDACs, MFP, and NETs, which enabled their differ-
ential diagnosis.
Several studies have attempted to characterize solid
pancreatic lesions using CE US. D’Onofrio et al. [21]
reported that 891 (90%) of the 987 PDACs were hypo-
vascular on SonoVue-enhanced US, and this finding was
useful for the differential diagnosis of solid pancreatic
lesions. Sofuni et al. [16] reported that 34 (87%) of the 39
PDACs were hypovascular on Levovist-enhanced US.
However, these reports also suggested that approxi-
mately 10% of PDACs showed isovascularity or hyper-
vascularity and could be easily misdiagnosed. Matsubara
et al. reported a time-intensity curve-based quantitative
analysis of CE harmonic endosonographic ultrasound
(EUS) for differentiating pancreatic diseases. They re-
ported that the echo-intensity reduction rate from the
peak to 1 min after Sonazoid injection was greater in
PDACs than in MFP and NETs [28]. In the present
study, vascularity of PDACs also decreased from the
arterial phase to the venous phase. We termed this
transition in vascularity as a ‘‘washout change,’’ which
refers to the change from hypervascular lesions in the
Table 3. Enhancement patterns after consensus meeting
PDAC MFP NET
Arterial phase
Hypervascular 3(2/64) 0(0/10) 64(7/11)
Isovascular 13(8/64) 90(9/10) 36(4/11)
Hypovascular 84(54/64) 10(1/10) 0(0/11)
Venous phase
Hypervascular 2(1/64) 0(0/10) 55(6/11)
Isovascular 5(3/64) 90(9/10) 36(4/11)
Hypovascular 94(60/64) 10(1/10) 9(1/11)
Vessel location
Peritumoral 48(31/64) 0(0/10) 0(0/11)
Intratumoral 52(33/64) 100(0/10) 100(11/11)
Vessel form
Fine 16(10/64) 90(9/10) 0(0/11)
Irregular 84(54/64) 10(1/10) 100(11/11)
Data are percentages; data in parentheses are numbers of the solid pancreatic lesions
PDAC pancreatic ductal adenocarcinoma, MFP mass-forming pancreatitis, NET neuroendocrine tumor
Table 4. Combinations of enhancement patterns
No. Combinations of enhancement patterns Positive predictive value Diagnostic pattern
Arterial phase Venous phase Vessel location Vessel form PDAC MFP NET
1 Hypervascular Hypervascular Intratumoral Irregular 0.14 (1) 0.86 (6) NET pattern
2 Hypervascular Isovascular Intratumoral Irregular 0.50 (1) 0.50 (1) Undefined
3 Isovascular Isovascular Intratumoral Fine 1.00 (8) MFP pattern
4 Isovascular Isovascular Intratumoral Irregular 0.33 (2) 0.17 (1) 0.50 (3) NET pattern
5 Isovascular Hypovascular Intratumoral Fine 0.86 (6) 0.14 (1) PDAC pattern
6 Hypovascular Hypovascular Peritumoral Fine 1.00 (8) PDAC pattern
7 Hypovascular Hypovascular Peritumoral Irregular 1.00 (23) PDAC pattern
8 Hypovascular Hypovascular Intratumoral Fine 0.67 (2) 0.33 (1) PDAC pattern
9 Hypovascular Hypovascular Intratumoral Irregular 1.00 (21) PDAC pattern
Data in parentheses are numbers of the solid pancreatic lesions
PDAC pancreatic ductal adenocarcinoma, MFP mass-forming pancreatitis, NET neuroendocrine tumor
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arterial phase to isovascular or hypovascular lesions in
the venous phase or from isovascular lesions in the
arterial phase to hypovascular lesions in the venous
phase. In the present study, 7 (70%) of the 10 PDACs
that were hypervascular of isovascular in the arterial
phase showed washout changes in the venous phase. In
contrast, all 10 cases of MFP and 9 (82%) of the 11 NETs
showed persistent enhancement during both the phases.
As an exception, 3 (5%) of the 64 PDACs showed per-
sistent enhancement and could not be differentiated from
MFP and NETs. In one PDAC case with persistent
enhancement, pathological findings of the resected
specimen revealed a feature with neuroendocrine differ-
entiation, and in the other two cases of PDAC, severe
inflammation was observed in the tumors.
In solid pancreatic lesions, vessel form is an impor-
tant feature for the differentiation of MFP and NETs.
Nine (90%) of the 10 MFP cases showed ﬁne vessels,
similar to pancreatic parenchyma, whereas all the NET
cases showed irregular vessels. The irregular vessels in
NETs were markedly dilated compared with those in
PDACs and MFP, with the exception of one (10%) MFP
case that showed irregular vessels, possibly because of
severe inﬂammation in the lesion. Regarding the vessel
location, peritumoral vessels were unique in PDAC
cases. Finally, nine combined enhancement patterns were
consensually obtained by the two readers. According to
PPV, these combination patterns were classiﬁed as a
PDAC, MFP, or NET pattern. These combination pat-
terns enabled us to perform a highly accurate differential
diagnosis of solid pancreatic tumors.
Several recent studies have suggested the usefulness of
CE harmonic EUS in the diagnosis of pancreatic disease
[28–31]. Compared with transabdominal US, EUS has
the advantages of higher spatial resolution and reduction
of artifacts from abdominal gas. However, the viewing
angle of EUS is smaller than that of transabdominal US;
therefore, it is often difficult to simultaneously depict
solid pancreatic lesions and pancreatic parenchyma.
Similar to 2D images, 3D US images enable us to
repeatedly check the acquired volume data frame by
frame.Moreover, CE 3DUShas the advantages of awider
volume angle and 3D viewing from various directions
because of the automatic volume data acquisition setting.
We can compare both the location and the vascularity of
solid pancreatic lesions and those of pancreatic paren-
chyma simultaneously in a single reconstructed plane.
These are helpful to determine the focal lesions in the
pancreas by tracing the dilated main pancreatic duct or
commonbile duct and to discern the anatomical structures
around the pancreas, such as the vessels or lymph nodes.
This study has several limitations. First, US of the
pancreas include artifacts such as those from abdominal
gas and motion, and calciﬁcation of the large vessels
surrounding the pancreas. Furthermore, the pancreatic
area behind the major vessels becomes hyper-echoic on
CE US imaging in the high MI contrast mode. In par-
ticular, the artifacts behind the gastroduodenal artery,
superior mesenteric artery, and superior mesenteric vein
may hinder the accurate evaluation of lesions in the
pancreatic head. Second, the number of MFP and NET
cases was less than the number of PDAC cases because
of the relatively low prevalence of MFP and NETs. This
may have biased the results of the present study; there-
fore, in the future, these results should be conﬁrmed
using a larger number of cases. Third, the diagnosis
criteria reported in this study were not applied prospec-
tively. Therefore, a prospective study using the
enhancement patterns-based classiﬁcation described in
this study is needed to conﬁrm its accuracy for the dif-
ferential diagnosis of solid pancreatic lesions.
In summary, we classiﬁed solid pancreatic lesions into
the combinations of enhancement patterns using CE 3D
US. We believe that this modality has clinical beneﬁts for
the accurate differential diagnosis of solid pancreatic le-
sions.
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